FDA to review naloxegol for OIC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted for review an NDA for naloxegol to treat opioid-induced constipation (OIC). The PDUFA date was not disclosed; the pharma declined to disclose details. The acceptance triggered a $70 million milestone payment from AstraZeneca to partner Nektar Therapeutics (NASDAQ:NKTR). The pharma has exclusive, worldwide rights to naloxegol from Nektar under an amended 2009 deal. The PEGylated form of naloxol, a peripheral mu opioid receptor ( OPRM1; MOR) antagonist, is also under review in Europe to treat OIC. ...